Autoimmune Pancreatitis: The Past, Present, and Future

Area of Science:

• Gastroenterology
• Immunology
• Pathology

Background:

• Autoimmune pancreatitis (AIP) was previously considered a single entity.
• The advent of the immunoglobulin G4 (IgG4) era has led to the classification of AIP into two distinct subtypes: type 1 (IgG4-related disease) and type 2 (granulocytic epithelial lesions).

Purpose of the Study:

• To delineate the characteristics, diagnostic criteria, and management challenges of the two proposed subtypes of autoimmune pancreatitis.
• To highlight the differences in clinical presentation, relapse rates, and long-term outcomes between type 1 and type 2 AIP.

Main Methods:

• Review of existing literature and diagnostic criteria, including the International Consensus Diagnostic Criteria.
• Characterization of clinical features, serological markers (serum IgG4), histopathological findings (lymphoplasmacytic sclerosing pancreatitis), and organ involvement in type 1 AIP.
• Analysis of treatment responses, relapse patterns, and potential long-term complications.

Main Results:

• Type 1 AIP is characterized by elevated serum IgG4, lymphoplasmacytic infiltration, fibrosis, obliterative phlebitis, and involvement of other organs, with a significant relapse rate (approx. 50% within 1 year).
• Type 2 AIP presents with granulocytic epithelial lesions.
• Diagnosis for both types relies on the International Consensus Diagnostic Criteria.

Conclusions:

• Type 1 AIP, a manifestation of IgG4-related disease, presents distinct features and a higher propensity for relapse compared to type 2.
• Current treatment consensus focuses on initial steroid therapy, but long-term management, especially for relapses, remains controversial.
• Further research is needed to identify specific biomarkers, alternative treatments for relapses, and elucidate the pathogenic mechanisms of AIP subtypes.